Floatz logo

Empegfilgrastim

Cancer

Moscow Clinical Scientific Centerprotein_peptideUnknownDormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

1380 Active assets in the Cancer cohort.

Asset / SponsorPhaseRating
Nabiximols
Jazz Pharmaceuticals
Phase 3BBB
Pyridoxol
M.D. Anderson Cancer Center
Phase 4BB
Rivoceranib
Jiangsu HengRui Medicine Co., Ltd.
Phase 4BB
Desflurane
Peter MacCallum Cancer Centre, Australia
Phase 4BB
Propofol
Hong Kong Children's Hospital
Phase 4BB

View all 50 →

Same molecule, other indications

Empegfilgrastim is also rated in:

digestive system cancerDormant
D
Indicative · Unknown
30 / 100
View asset →
female reproductive system neoplasmDormant
D
Indicative · Unknown
30 / 100
View asset →
myelosuppression, non-human animalDormant
D
Indicative · Unknown
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →